Skip to Content

Rydex Health Care Inv RYHIX

Medalist Rating as of | See Rydex Investment Hub
  • NAV / 1-Day Return 43.32  /  +0.35 %
  • Total Assets 25.9 Mil
  • Adj. Expense Ratio
    1.390%
  • Expense Ratio 1.390%
  • Distribution Fee Level Above Average
  • Share Class Type No Load
  • Category Health
  • Investment Style Large Blend
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield
  • Turnover 268%

USD | NAV as of Feb 23, 2024 | 1-Day Return as of Feb 23, 2024, 11:18 PM GMT+0

Morningstar’s Analysis RYHIX

Will RYHIX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Rydex Health Care Inv's Average Process Pillar and People Pillar ratings result in a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RYHIX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 21.9
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Other Assets & Liabilities

11.80 2.7 Mil

Eli Lilly and Co

2.96 675,604
Healthcare

UnitedHealth Group Inc

2.87 655,455
Healthcare

Johnson & Johnson

2.59 590,126
Healthcare

Merck & Co Inc

2.26 515,229
Healthcare

AbbVie Inc

2.24 511,401
Healthcare

Thermo Fisher Scientific Inc

1.95 445,333
Healthcare

Abbott Laboratories

1.88 428,282
Healthcare

Danaher Corp

1.71 389,808
Healthcare

Amgen Inc

1.69 386,235
Healthcare